Oramed Reports Positive Results from a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
News Jul 22, 2009
Oramed Pharmaceuticals, Inc. has reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients.
The completion of this study marks Oramed's first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed’s trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients.
Oramed’s oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion.
Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, “These results demonstrate that Oramed’s oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal.”
Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE